Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yi-Ke-Ding Tablets
- Development stage
- Phase 3
- Lead developer
- Jiangxi Huiren Pharmaceutical
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Yi-Ke-Ding Tablets (依可定片) is a traditional Chinese medicine (TCM) tablet developed by Jiangxi Huiren Pharmaceutical and the West China Hospital of Sichuan University for the treatment of chronic cholecystitis with dampness-heat syndrome. Classified as a Class 5 TCM new drug, its development has been supported by China's National 863 Program. Yi-Ke-Ding Tablets are formulated to clear dampness and heat, and have been evaluated in a multicenter, randomized, double-blind, double-dummy, parallel-group Phase III clinical trial in China.
- Other names
- Yikeding Tablets依可定依可定片
Beyond the preview
Go deeper on Yi-Ke-Ding Tablets.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yi-Ke-Ding Tablets.